Onco Actu du 11 juin 2018

	3.1.1 Prévention - Tabac - e-cigs
Ex-smokers might be better off with high rather than low nicotine e-cigs [Cancer Research UK] Researchers, based at London South Bank University, studied 20 e-cigarette users and found that people using low nicotine e-liquid in their devices puffed more deeply and more often than those using high nicotine liquid. Those using low nicotine also increased the power of their vaping devices when possible.
Vaping essays: E-cigarette sellers offering scholarships [AP] The tactic is taken from a method that was once believed to improve a site’s ranking in search results, and it has successfully landed vaping brands on the sites of some of the nation’s best-known universities, including Harvard. It also has drawn criticism that the scholarships are a thinly disguised ploy to attract young customers.
	4.5 Dép., diag. & prono. - Colorectal
How Early Is Too Early To Get A Colon Screening? [FiveThirtyEight] So what’s a 45-year-old to do? The answer to that will depend on that person’s individual circumstances and their value judgements about the risks and benefits.
	5.1 Traitements - Pré-clinique
Scientists Pinpoint a New Cause of Resistance to EGFR-Targeting Drugs [Memorial Sloan Kettering Cancer Center] By comparing which mutations occurred repeatedly across different experiments, the team was able to home in on one gene that seemed to confer resistance when it was turned on. That gene is YES1.
	5.10 Traitements - Essais
Selumetinib Continues to Show Promise in Children with NF1 [NCI] The phase 2 trial, which involves 50 patients aged 2 to 18 with NF1 and plexiform neurofibromas, confirms the results of a smaller trial that in 2016 demonstrated for the first time that the drug could shrink large tumors.
Protecting the accuracy of clinical trial data in China [BMJ Blogs] The implementation of this platform will not only protect trial data and ensure its accuracy, but also benefit the internal/external monitors and auditors, and the researchers themselves.
Going further to make all clinical trials public [MRC] The NIH is by far the largest non-commercial funder of clinical trials in the world and so when it changes, it changes the baseline for what a funder could do. We hope it will show organisations who are already doing well – like the MRC – that there is still further they can go.
	5.12.5 Immunothérapies - Pharma
Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie [EndPoints] Another transpacific biotech has launched with the backing of an emerging group of venture investors in China as well as a plan to build a pipeline of cancer drugs that can be swiftly developed for the booming Asian market. Not surprisingly, they’re getting started by focusing on drug combinations using red-hot checkpoint therapies to amp up responses for targeted therapies.
	5.12.7 Immunothérapies - vaccins
Advaxis cuts staff as it seeks partner for troubled cancer vaccine [FierceBiotech] Just six weeks after taking the helm of biotech Advaxis, CEO Ken Berlin has launched a search for a partner for its stalled lead axalimogene filolisbac (AXAL) and will scale back trials of the immunotherapy in order to bring earlier stage programs forward. It will also eliminate almost a quarter of its workforce.
	5.2 Pharma
Ipsen moves U.S. headquarters to Kendall Square [FierceBiotech] Paris-based Ipsen established a toehold in the city in 2014 and went on to boost its presence last year through a $1.25 billion deal with Merrimack. Now, Ipsen is moving its U.S. headquarters from New Jersey to Kendall Square, positioning it to add more than 200 people to its Cambridge workforce in the years to come.
After snatching up Shire’s cancer unit, French pharma giant Servier to expand US presence with Kendall Square innovation office [EndPoints] This marks the second French pharma giant to announce a Kendall Square outpost in the past 24 hours. Just yesterday, Ipsen announced it was moving its US headquarters from New Jersey to Boston.
	5.3.4 Traitements - AMM (FDA, EMA,...)
The EU approves Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer [AstraZeneca] Today the European Commission has granted marketing authorisation for Tagrisso (osimertinib) as monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. The approval is based on results from the Phase III FLAURA trial published in the New England Journal of Medicine.
AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy [AbbVie] In the MURANO Phase 3 clinical trial, the VENCLEXTA® (venetoclax tablets) plus rituximab combination showed a significant improvement in progression-free survival (PFS) for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, reducing the risk of disease progression or death by 81 percent when compared to a standard of care chemoimmunotherapy regimen, bendamustine plus rituximab.
	5.4 Traitements - Economie
Merck impresses NICE with Keytruda data—and discounts—cueing up a CDF switch [FiercePharma] Previously, Keytruda was available for first-line use, but only for patients who applied for special funding through England’s Cancer Drugs Fund. Now, though—assuming the recommendation holds when NICE publishes final guidance later this month—about 1,800 patients per year will no longer have to jump through those hoops.
To all involved — we have a problem [Nature Reviews Clincal Oncology] We have a problem: the rising cost of anticancer therapies and the current regulatory environment have helped to create an unsustainable (and unacceptable) situation. This problem frequently receives attention in our journal — and we consider that our duty is to do so. This is a call to all stakeholders to state what their position is in face of this problem.
	5.5.1.1 ASCO (général) - Industriels
Visualize: ASCO 2018’s winners and losers [EndPoints] We created this chart based on data compiled by EP Vantage to show you just how influential ASCO data can be. In Roche’s case, it destroyed $17.4 billion in market cap value. Merck’s ASCO news, however, created $4.4 billion.
	6.1 Observation
Low-fat diet tied to improved breast cancer survival odds [Reuters] Researchers studied 19,541 participants in the federally funded Women’s Health Initiative (WHI) who were randomly selected to join a dietary experiment focused on limiting fat intake to 20 percent of calories. Researchers also looked at data for a control group of 29,294 women in the WHI study who didn’t alter their diets.
	6.10 Politiques
The fight has begun over Europe’s big budget increase for science [Science] European universities are unhappy about the details, announced yesterday, of Horizon Europe, the European Union’s new 7-year research program that will start in 2021. They say the 22% increase in funding overall proposed by the European Commission is the bare minimum and worry that the program shortchanges basic research in favor of innovation funding.
EU to world: join our €100-billion research programme [Nature] European Commission’s next seven-year science-funding scheme — its biggest ever — will allow any country to join for a price.
	6.10.1 Politiques (USA)
STAR Act Aims to Boost Pediatric Research [Cancer Research Catalyst] This week, President Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which is aimed at supporting pediatric cancer research. The legislation calls for expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.
	6.11 Patients
You, Me and the Big C: 'When you talk about cancer, you normalise it' [The Guardian] Launched in March, the BBC podcast is about something that on paper sounds very hard to sell: what it’s like to have cancer, presented by a woman who has it (Bland), and two who have recently gone into remission (James and Mahon).
	6.7.1 IA/bioinformatique
AI cancer detectors [The Guardian] Researchers suggest artificial intelligence is now better and faster at detecting cancer than clinicians.